Actualités
Communiqué de Presse
08/02/2022
SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment
Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.
Communiqué de Presse
04/11/2021
ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease
Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia
Actualités
28/10/2021
Oncodesign: EHDEN Certified SME
EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.
Communiqué de Presse
25/10/2021
Oncodesign has appointed Karine Lignel as Group Chief Development Officer
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
Communiqué de Presse
21/10/2021
Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
Communiqué de Presse
05/07/2021
Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors
Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.
Actualités
02/07/2021
Our brand Oncodesign
Our brand Oncodesign . Combination of the words oncology and design... Precision Medicine for patient... Oncodesign Services
Actualités
02/07/2021
Find out how we built our logo!
Oncodesign Services Find out how we built our logo! trajectory DNA innovation...green and bleue pharma colors Find out how we built our logo!
Communiqué de Presse
01/07/2021
Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT
Discover the alliance of experts in radiopharmaceuticals: an innovative offer in therapeutic development in nuclear medicine from the validation of therapeutic targets, the generation of radiolabeled biological vectors, the optimization of leads, the generation of drug candidates to IND, the design and management of clinical trials.
Actualités
01/07/2021
Brand new logo for Oncodesign
Brand new logo for Oncodesign. New graphic identity with evolutive look & feel approach... First element of our new logo.
Communiqué de Presse
28/06/2021
Oncodesign launches its new DRIVE-MRT™ service offer in partnership with Covalab, CheMatech and ABX-CRO
[Press Release] Explore our brand new service offer DRIVE-MRT. it allows the rationalization, design and optimization of targeted radiopharmaceutical products that are effective against certain metastatic cancers.
Communiqué de Presse
24/06/2021
Oncodesign provides an update on its progress on RIPK2
[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.